{"pmid":32303591,"title":"Cytokine release syndrome in severe COVID-19.","text":["Cytokine release syndrome in severe COVID-19.","Lessons from arthritis and cell therapy in cancer patients point to therapy for severe disease.","Science","Moore, By John B","June, Carl H","32303591"],"abstract":["Lessons from arthritis and cell therapy in cancer patients point to therapy for severe disease."],"journal":"Science","authors":["Moore, By John B","June, Carl H"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303591","week":"202016|Apr 13 - Apr 19","doi":"10.1126/science.abb8925","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664431720510783488,"score":8.233237,"similar":[{"pmid":32234467,"pmcid":"PMC7118634","title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","text":["The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.","Int J Antimicrob Agents","Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang","32234467"],"abstract":["Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234467","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105954","keywords":["COVID-19","Cytokine release syndrome","Tocilizumab"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["tocilizumab"],"_version_":1663352135625998336,"score":94.409615},{"pmid":32271462,"title":"Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?","text":["Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?","The outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection.","Eur Rev Med Pharmacol Sci","Bizzarri, M","Lagana, A S","Aragona, D","Unfer, V","32271462"],"abstract":["The outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Bizzarri, M","Lagana, A S","Aragona, D","Unfer, V"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271462","week":"202015|Apr 06 - Apr 12","doi":"10.26355/eurrev_202003_20715","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Inositol"],"_version_":1663620083136593920,"score":88.88438},{"pmid":32291137,"title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","text":["Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application.","J Autoimmun","Liu, Bingwen","Li, Min","Zhou, Zhiguang","Guan, Xuan","Xiang, Yufei","32291137"],"abstract":["The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application."],"journal":"J Autoimmun","authors":["Liu, Bingwen","Li, Min","Zhou, Zhiguang","Guan, Xuan","Xiang, Yufei"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291137","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaut.2020.102452","keywords":["Coronavirus disease 2019","Cytokine release syndrome","Interleukin-6","Tocilizumab"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266295632199680,"score":84.83064},{"pmid":32202240,"title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","text":["COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.","Clin Exp Rheumatol","Sarzi-Puttini, Piercarlo","Giorgi, Valeria","Sirotti, Silvia","Marotto, Daniela","Ardizzone, Sandro","Rizzardini, Giuliano","Antinori, Spinello","Galli, Massimo","32202240"],"abstract":["A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs."],"journal":"Clin Exp Rheumatol","authors":["Sarzi-Puttini, Piercarlo","Giorgi, Valeria","Sirotti, Silvia","Marotto, Daniela","Ardizzone, Sandro","Rizzardini, Giuliano","Antinori, Spinello","Galli, Massimo"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202240","week":"202013|Mar 23 - Mar 29","link_comment_in":"32207680","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352133629509633,"score":83.80313},{"pmid":32277367,"title":"Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","text":["Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points* Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.* Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.* Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.","Clin Rheumatol","Misra, Durga Prasanna","Agarwal, Vikas","Gasparyan, Armen Yuri","Zimba, Olena","32277367"],"abstract":["The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points* Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.* Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.* Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice."],"journal":"Clin Rheumatol","authors":["Misra, Durga Prasanna","Agarwal, Vikas","Gasparyan, Armen Yuri","Zimba, Olena"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277367","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s10067-020-05073-9","keywords":["COVID-19","Epidemiology","Hydroxychloroquine","Hypothesis","Immunity","Pathogenesis","Vaccines","Vitamin D"],"source":"PubMed","locations":["thrombocytopenia","Cytokine","myocarditis","leucopenia","lymphopenia","thrombocytopenia"],"topics":["Treatment"],"weight":1,"e_drugs":["lopinavir-ritonavir drug combination","Ibuprofen","tocilizumab","Hydroxychloroquine","Chloroquine","remdesivir","favipiravir"],"_version_":1663798882933407744,"score":71.46599}]}